Giving bharglob vaccine..anything to be cautious about
Reading File
Finding Sources
Searching the Web
bharglob vaccine precautions contraindications
Good - Bharglob is not a vaccine. It is Human Normal Immunoglobulin (16.5%) Injection, made by Bharat Serums & Vaccines Ltd. (India). It's a passive immunotherapy product - a pooled human immunoglobulin preparation, not an active vaccine. Here's a full breakdown of what to watch out for:
Bharglob 16.5% Injection - Key Cautions
What it is: Human Normal Immunoglobulin (HNIG) 16.5% - a preparation of pooled human antibodies (IgG) used for passive immunity. Made by Bharat Serums & Vaccines Ltd.
Contraindications (DO NOT give if...)
- IgA deficiency - patients with selective IgA deficiency who have anti-IgA antibodies are at high risk of severe anaphylaxis
- Known hypersensitivity to immunoglobulins or any component of the preparation
- Hypersensitivity to human immunoglobulin in general
Precautions - High Priority
Renal:
- Can cause acute renal failure, especially with high doses or rapid infusion
- Use with caution in patients with pre-existing kidney disease, diabetes, volume depletion, age >65, or those on nephrotoxic drugs
- Monitor renal function before and during use
Thrombotic events:
- Risk of deep vein thrombosis (DVT), pulmonary embolism, stroke, and MI - particularly in patients with blood clotting disorders, vascular disease, or prolonged immobility
- Use minimum effective dose and ensure adequate hydration
Hemolysis:
- May cause hemolytic anemia - monitor for signs of hemolysis
Aseptic meningitis syndrome:
- Rare but reported - presents with headache, fever, nausea, vomiting, nuchal rigidity, photophobia
Drug Interactions
| Interacting Drug/Class | Concern |
|---|---|
| Live vaccines (measles, MMR, polio, varicella) | Immunoglobulin can neutralize live vaccine antigens - defer live vaccines for 3 months after HNIG |
| Blood thinners (warfarin, heparin) | Potential interaction - monitor closely |
| Immunosuppressants (cyclosporine, tacrolimus) | May alter efficacy |
Special Populations
- Pregnancy: Limited data - use only if clearly indicated by a doctor
- Breastfeeding: Passes into breast milk - use under medical supervision
- Driving: May cause dizziness - caution advised
Administration Cautions
- Must be administered by a healthcare professional (doctor or nurse) - not for self-administration
- Patient should be monitored for at least 20-60 minutes post-injection for anaphylaxis or infusion reactions
- Common infusion reactions: headache, fever, nausea, vomiting, dizziness, flushing, injection site pain/redness/swelling
- Store at 2-8°C - do NOT freeze
The Most Important Practical Points
- Always screen for IgA deficiency before giving - anaphylaxis risk is severe
- Space it away from live vaccines - at least 3 months gap
- Go slow with infusion rate - faster rates increase risk of renal and cardiovascular adverse effects
- Monitor renal function in at-risk patients
- Watch for delayed hemolysis - can occur days after administration
This is a shared conversation. Sign in to Orris to start your own chat.